Article Correctness Is Author's Responsibility: PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients

Newswise imageResearchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival (PFS) for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.